Last updated on March 2018

Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)

Brief description of study

This study is a Phase 2, randomized, placebo controlled, dose ranging study of piromelatine (5, 20, and 50 mg daily for 6 months) versus placebo to determine an effective dose based on efficacy (cognitive performance), safety and tolerability in patients with mild dementia due to AD.

Clinical Study Identifier: TX198914

Find a site near you

Start Over

Meridien Research - Spring Hill

120 Medical Boulevard, #103 Spring Hill, FL USA
  Connect »